Skip to search formSkip to main contentSkip to account menu

0.8 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe

Known as: FONDAPARINUX SODIUM 10 mg in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [Fondaparinux Sodium], FONDAPARINUX NA 10MG/0.8ML INJ,SYRINGE,0.8ML [VA Product], FONDAPARINUX 10MG/0.8ML INJ SYR 0.8ML 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BackgroundPharmacological thromboprophylaxis after colorectal cancer (CRC) surgery is internationally recommended for venous… 
2013
2013
Anti‐PF4/heparin antibodies are frequently generated after coronary artery bypass grafting (CABG) surgery, with platelet… 
2012
2012
Summary.  Background:  Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic… 
2012
2012
PurposeFondaparinux, a selective activator factor X (factor Xa) inhibitor, is effective and safe for preventing venous… 
2010
2010
Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke - 
Review
2006
Review
2006
CONTEXT Fondaparinux, a factor Xa inhibitor, is approved for thromboprophylaxis after orthopedic surgery and for treatment of…